May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
Sep 17, 2019
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
Oct 30, 2018
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
Oct 29, 2018
CStone announces first patient dosed in Phase I study in China for MEK inhibitor CS3006
Sep 20, 2018
European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma
Sep 13, 2018
Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
Aug 14, 2018
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
Jul 27, 2018
BRAFTOVI(TM) (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Jul 13, 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Jun 28, 2018
Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI® (binimetinib)
Jun 23, 2018
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer
Jun 20, 2018
CStone enrolls first patient in Phase I study for MEK inhibitor CS3006 in Australia
Jun 04, 2018
Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma
May 16, 2018
Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting
Apr 20, 2018
Global Melanoma Market Report 2018 - Anticipated to Reach a Market Value of $14 Billion by 2024
Mar 22, 2018
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
Feb 06, 2018
Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
Dec 27, 2017
CStone files MEK inhibitor CS3006 for clinical trial approval in Australia
Nov 17, 2017
Melanoma: KOL Insight 2016
Nov 06, 2017
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer